Source: PIB| Date: March 29, 2026
Why This Meeting Is More Than Routine Governance
On the surface, the inaugural meeting of the BRIC Research Advisory Board looks like standard institutional housekeeping — a new body holds its first meeting, directors give presentations, experts deliberate, and a webinar wraps things up. Routine.
It is anything but.
To understand why, you need to appreciate the scale of what BRIC represents. The Biotechnology Research and Innovation Council was formed by subsuming not one or two, but 14 autonomous institutes of the Department of Biotechnology into a single apex body. In the history of Indian science administration, this ranks among the most ambitious consolidations ever attempted. Each of those 14 institutes had its own culture, its own leadership, its own research priorities, its own staff expectations, and — critically — its own political constituencies within the scientific community.
Merging them is not a bureaucratic formality. It is an act of institutional surgery, and the BRIC-RAB is, in effect, the body responsible for ensuring the patient survives and thrives.
The inaugural meeting at the Regional Centre for Biotechnology in Faridabad was therefore the first serious test of whether the post-merger architecture has the intellectual and governance depth to deliver on its mandate. The two-day format — dense with presentations, ideation sessions, panel discussions and an open webinar — suggests that the intent, at least, is serious.
The Architecture of BRIC: Understanding What Was Built Before the RAB Met
To analyse what the RAB meeting means, one must first understand the structure it is overseeing.
BRIC is described as an Apex Autonomous Body, established as a registered Society. This legal form matters. A registered Society has more operational flexibility than a standard government department — it can, in principle, move faster on hiring, procurement, and collaboration agreements. The "autonomous" designation suggests insulation from routine bureaucratic interference, though in practice, autonomy in Indian public institutions exists on a spectrum.
The institutes under BRIC's umbrella — referred to as iBRIC — collectively represent decades of accumulated scientific capacity across domains including genomics, bioinformatics, structural biology, agricultural biotechnology, environmental science, neuroscience, and more.
Alongside iBRIC, the meeting also included representatives from RCB (Regional Centre for Biotechnology) and ICGEB (International Centre for Genetic Engineering and Biotechnology), collectively termed iBRIC+. The inclusion of ICGEB is particularly noteworthy — it is an intergovernmental organisation headquartered in New Delhi with a global mandate, and its participation signals that BRIC is positioning itself for international scientific engagement, not just domestic consolidation.
The Research Advisory Board sits as the strategic oversight layer. Its mandate is threefold: guiding research direction, reviewing ongoing activities, and monitoring performance. But the inaugural meeting revealed a fourth, arguably more important function — co-architecting the transformation itself. Dr. Rajesh S. Gokhale, Secretary of DBT and Director General of BRIC, explicitly described RAB members as "co-architects of BRIC transformation." This framing is significant. It positions the RAB not as a passive review committee, but as an active participant in shaping what BRIC becomes.
The Chairperson: Why Prof. VijayRaghavan's Role Deserves Attention
The choice of Prof. K. VijayRaghavan as RAB Chairperson is not incidental. It is a deliberate signal about the kind of leadership the government wants at the helm of this exercise.
VijayRaghavan is a developmental biologist of international standing, former Secretary of DBT, and most recently Principal Scientific Adviser (PSA) to the Government of India — arguably the most influential science policy role in the country. His tenure as PSA was marked by a distinctive intellectual style: systemic thinking, emphasis on interdisciplinarity, and a consistent push to connect India's scientific output to broader national challenges.
His remarks at the inaugural meeting reflect this worldview. He spoke about multidisciplinary teams as essential to modern scientific problem-solving — a point that sounds obvious but is, in practice, deeply countercultural in Indian academia, which remains organised primarily around disciplinary silos.
He articulated the "bio-revolution" as generating problems of unprecedented scale and complexity, requiring "open knowledge sharing, resource optimisation, shared infrastructure, and continuous, iterative ideation." This is not the language of conventional science administration. It is the language of systems design.
The significance of VijayRaghavan chairing this body is that he has both the scientific credibility to command respect from institute directors and the policy experience to navigate the bureaucratic and political dimensions of running a national apex body. Whether that combination is sufficient to drive the transformation BRIC envisions is another question — but the appointment is, at minimum, the right one.
The Core Strategic Themes: A Detailed Unpacking
1. Decentralization Within Coherence — The Hardest Governance Problem
The meeting described BRIC's goal as becoming a "cohesive, decentralized national biotechnology laboratory." This phrase deserves to be examined carefully, because it contains a fundamental tension.
Decentralization is attractive for good reasons. Scientific creativity flourishes when researchers have autonomy — to choose problems, design experiments, and pursue unexpected leads. Excessive centralisation produces conformity, bureaucratic bottlenecks, and institutional conservatism. The history of Soviet science is the cautionary tale here.
Coherence, however, is also necessary — particularly for a body with a national mandate and public funding accountability. Without coherence, you get 14 institutes doing their own things, duplicating infrastructure, competing rather than collaborating, and failing to add up to anything larger than the sum of their parts. That was, arguably, the very problem that prompted BRIC's creation in the first place.
Threading this needle requires very precise institutional design: clear mission alignment at the top, genuine operational autonomy at the level of individual laboratories and researchers, and a performance framework that rewards both disciplinary excellence and cross-institutional collaboration. The meeting discussed a performance framework matrix for BRIC scientists — this is one of the most consequential design choices BRIC will make. Get it right, and researchers understand what is expected and feel ownership over their career trajectories. Get it wrong, and you generate perverse incentives, gaming behaviour, and talent exit.
The details of this framework were not publicly disclosed, but the fact that it was discussed at the inaugural RAB meeting — rather than being treated as an administrative afterthought — is encouraging.
2. Sovereign Technology: The Geopolitical Dimension of Biotech Policy
The meeting's emphasis on developing sovereign technologies in support of Viksit Bharat places BRIC's work squarely within India's broader strategic posture of technological self-reliance.
This language has specific meaning in the current global context. The COVID-19 pandemic exposed the vulnerability of nations that depended on others for critical biologics — vaccines, diagnostics, therapeutics. The subsequent global scramble for mRNA technology, the export restrictions on raw materials, and the intellectual property battles over vaccine formulations were a live demonstration of what "technology dependency" means in a crisis.
India, despite being the world's largest vaccine manufacturer by volume, found itself in a position of depending on foreign-owned technology for some of the most critical products.
The sovereign technology agenda is a direct response to that lesson. It encompasses several distinct goals:
- Platform technologies — developing indigenous mRNA, viral vector, and protein subunit vaccine platforms rather than licensing them from foreign entities
- Diagnostic and genomic tools — building domestic capacity for sequencing, screening, and surveillance rather than depending on imported reagents and instruments
- Agricultural biotechnology — developing crop varieties, pest resistance solutions, and biofertilisers suited to Indian conditions, not adapted from foreign germplasm
- Bioinformatics and AI tools — building data infrastructure and analytical platforms that keep India's genomic and biodiversity data within sovereign control
The meeting's discussion of India's rich biodiversity and extensive data resources as competitive advantages is strategically astute. India is one of the world's 17 megadiverse countries — a repository of biological material and traditional knowledge that represents an extraordinary raw material for biotechnology innovation, provided the institutional capacity exists to work with it systematically.
Similarly, India's demographic scale means that genomic databases built on Indian population data could have both scientific value — populations with distinct genetic histories — and commercial value in drug discovery and personalised medicine.
The geopolitical dimension here is significant: control over biodiversity data and genomic datasets is increasingly a matter of national security, not just scientific policy.
3. Biomanufacturing Hubs and Biofoundries — The Infrastructure That Changes Everything
Of all the concrete developments mentioned in the meeting report, the network of biomanufacturing hubs and biofoundries within BRIC is arguably the most economically significant.
Understanding why requires a brief explanation of what biofoundries actually do. A biofoundry is a facility that combines automated laboratory equipment, computational design tools, and standardized biological parts to enable rapid design-build-test-learn cycles in synthetic biology.
Think of it as a factory for biological prototyping — where researchers can go from a design concept to a tested biological construct in days rather than months.
The economic logic of biofoundries is compelling. Biological research has historically been slow, expensive, and difficult to scale because each experiment required skilled human labour.
Biofoundries change this by automating the most repetitive steps, enabling high-throughput screening, and dramatically compressing development timelines. For a country trying to accelerate its biotech sector, access to biofoundry infrastructure is not a luxury — it is a competitive necessity.
Biomanufacturing hubs serve a complementary function: they provide the scale-up infrastructure needed to take a proven biological design and produce it in commercial quantities. This is the bottleneck where most promising Indian biotech research has historically stalled. Academic labs can produce discoveries; biomanufacturing hubs can convert those discoveries into products.
The combination of biofoundries for rapid prototyping and biomanufacturing hubs for scale-up represents, if properly resourced and managed, a genuine step-change in India's capacity to translate research into economic output.
BRIC's positioning at the "forefront of the emerging bio-based economy" through this infrastructure network is not hyperbole — it is a plausible near-term reality, provided the investment and management are sustained.
4. Frugal Innovation and Design Intelligence — India's Distinctive Competitive Strategy
The discussions around frugal innovation and design intelligence are among the most intellectually interesting elements of the meeting, because they point toward a genuinely Indian approach to biotechnology rather than an imitative one.
Frugal innovation is sometimes misunderstood as simply "cheap science." It is not. At its best, frugal innovation means designing from first principles for the actual constraints of a given context — cost, infrastructure availability, skill levels, regulatory environment, cultural preferences — rather than adapting expensive solutions designed for different contexts.
India has produced some of the world's most celebrated examples of frugal innovation in healthcare: the Jaipur Foot, the electrocardiograph designed for rural conditions, neonatal care innovations that dramatically cut infant mortality costs.
The application of this philosophy to biotechnology is potentially transformative. Most global biotech infrastructure is designed for high-income country laboratories — expensive equipment, controlled environments, highly trained operators, reliable cold chains. For the majority of India's geography and economic reality, much of this is impractical.
Designing biotech tools and processes that work in these conditions — using locally sourced materials, simpler equipment, robust protocols — opens markets and applications that expensive imported solutions cannot reach.
Design intelligence as a concept extends this further: it suggests not just cost reduction but active intellectual design optimised for Indian conditions. This is a sophisticated framing that moves beyond the defensive crouch of "we can't afford Western biotech" to the offensive posture of "we can design better biotech for our conditions than anyone else."
The strategic implications are significant. If India can develop frugally designed, robust biotech tools — for diagnostics, agricultural applications, environmental monitoring, industrial bioprocessing — it does not just serve the domestic market. It creates exportable solutions for the global south, where similar constraints apply. This is a potential $100-billion+ market that Western biotech companies are structurally poorly positioned to serve.
5. Inter-Institutional Collaboration — Cultural Change as the Real Challenge
The meeting placed considerable emphasis on inter-institutional collaboration — sharing laboratories, resources, and expertise across BRIC institutes. This is, on paper, one of the most obvious benefits of consolidation. In practice, it is one of the hardest things to achieve in academic science.
The culture of scientific institutions — anywhere in the world, but particularly in India — tends toward territorial behaviour. Principal Investigators guard their equipment, their graduate students, their grant relationships, and their publication pipelines. Directors protect their institute's budget allocations and headcounts. Collaboration, when it happens, tends to be between individuals who trust each other, not between institutions as a matter of policy.
BRIC's consolidation creates the structural conditions for collaboration — shared ownership, unified governance, common infrastructure. But structural conditions are necessary, not sufficient. The cultural change required is deeper and slower. It requires incentive systems that reward collaborative output (joint publications, shared patents, co-supervised students) rather than just individual institute metrics.
It requires physical infrastructure — shared instruments, common data platforms, connected biobanks — that makes collaboration the path of least resistance. And it requires leadership at the institute director level that models collaborative behaviour rather than competitive positioning.
The discussion of a performance framework matrix is relevant here. If the framework measures BRIC scientists purely on individual output — their own papers, their own grants — collaborative behaviour will remain an add-on rather than a core expectation. If it meaningfully weights cross-institutional contributions, the incentive landscape changes.
6. The Bioeconomy Vision — Scale, Ambition, and the Industry Question
The overarching frame of the meeting is India's bioeconomy — a term that refers to the economic value generated from biological resources, processes, and systems. India has set ambitious targets in this domain, with government projections pointing toward a $300 billion bioeconomy by 2030.
Whether that figure is realistic is debatable. What is not debatable is that the bioeconomy is a genuine and growing global opportunity. Synthetic biology, precision fermentation, biological manufacturing, agricultural biotech, and bio-based materials are converging into one of the most significant economic transitions since the information technology revolution. Countries that build strong positions in this space in the next decade will have durable competitive advantages for generations.
BRIC's role in this is intended to be foundational — generating the research, building the talent, developing the platforms, and creating the infrastructure that a thriving bioeconomy requires. The meeting's discussion of industry linkages is therefore not peripheral — it is central to whether BRIC's research output actually translates into economic value.
This is where the hardest questions arise. India's track record on academic-industry collaboration in biotechnology is mixed. There are success stories — the vaccine manufacturers, some agricultural biotech companies, a growing crop of biotech startups. But the pathway from publicly funded research to commercial products remains poorly institutionalised. Technology transfer offices at Indian institutions are often understaffed and under-resourced. IP frameworks can be ambiguous. Regulatory pathways for novel biologics are sometimes slow and unpredictable.
The meeting acknowledged the need to "build strong linkages with industry to create a robust bioeconomy," but the specific mechanisms — licensing arrangements, sponsored research agreements, equity participation, co-development models — were not detailed in the public communication.
These details matter enormously. The difference between a well-designed and a poorly designed industry collaboration framework is not marginal — it is the difference between research that generates economic value and research that generates papers.
What Was Not Said — The Gaps Worth Noting
A thorough analysis must also address what the meeting report does not tell us.
Funding quantum. The meeting discussed "how best to utilise the core budget of iBRIC+" but gave no indication of what that budget actually is. The scale of BRIC's ambitions — biofoundries, biomanufacturing hubs, inter-institutional infrastructure, talent development — requires substantial and sustained investment. Without clarity on funding levels and trajectories, the vision remains aspirational.
Talent pipeline specifics. The goal of generating "strong biotech leaders of the future" was mentioned, but no specifics about fellowship programmes, faculty recruitment targets, international exchange arrangements, or PhD pipeline expansion were publicly discussed. India's most acute constraint in scaling its biotech sector is not ideas or even money — it is the availability of trained scientists and engineers at every level of the value chain.
Regulatory reform. For all the discussion of moving from consumer to innovator, India's regulatory environment for novel biotechnology products — gene-edited crops, novel biologics, cell and gene therapies — remains one of the most significant bottlenecks. BRIC can generate world-class science, but if regulatory pathways are slow, opaque, or unpredictable, the translation to products will lag regardless of research quality. The meeting's public communication made no reference to regulatory reform advocacy.
International partnerships. Beyond ICGEB's participation, the meeting report gives little indication of how BRIC plans to position itself in the global scientific community — which foreign institutions it will partner with, how it will attract international collaborators, and how Indian scientists within BRIC will maintain exposure to cutting-edge global science. In a field advancing as rapidly as biotechnology, isolation from the global scientific conversation is a serious risk.
The Verdict: Promise, Precisely Calibrated
The inaugural BRIC-RAB meeting represents a genuine moment of institutional seriousness in Indian science policy. The governance architecture is thoughtfully constructed. The leadership is credible. The strategic themes — sovereign technology, biomanufacturing infrastructure, frugal innovation, inter-institutional collaboration — are the right ones. The framing of India's biodiversity and data assets as competitive advantages is sophisticated.
But vision statements at inaugural meetings are easy. What follows is harder.
BRIC's transformation will be measured not by the quality of deliberations in Faridabad in March 2026, but by whether, five years from now, India has demonstrably better translation infrastructure between discovery and product; whether BRIC scientists are producing research with global impact AND domestic economic relevance; whether the biofoundry network is operational and heavily used; whether industry partnerships are generating actual products; and whether the next generation of Indian biotech leaders credits BRIC as the institution that shaped them.
